Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 1Stomach Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 26Nivolumab 10Docetaxel 8avelumab 7atezolizumab 7Gemcitabine 7Carboplatin 6Trastuzumab 5Ipilimumab 5Radiosurgery 4Psychiatric Rehabilitation 4Immunoglobulin G 4Early Intervention, Educational 4Cyclophosphamide 4fludarabine 3durvalumab 3cemiplimab 3Taxes 3Radiotherapy 3Polymerase Chain Reaction 3Gene Expression Profiling 3Disulfides 3Counseling 3Cisplatin 3Blood Specimen Collection 3Biopsy 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3zimberelimab 2utomilumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × eprenetapopt × Thoracic × Clear all
NCT04383938 2025-05-13

Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies

Aprea Therapeutics

Phase 1/2 Completed
40 enrolled 11 charts
GastrointestinalGenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡